ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2025
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • 2020-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstracts tagged "meta-analysis"

  • Abstract Number: 0670 • ACR Convergence 2025

    Clinical Significance of Therapeutic Drug Level Monitoring for Mycophenolate in Patients With Extra-renal Systemic Lupus Erythematosus – A Systematic Review & Meta-analysis

    Zahraa Qamhieh1, Dalia Sriwi1, Callie Saric2, Tripti Singh3, Christie Bartels4 and Shivani Garg5, 1University of Wisconsin, Madison, Department of Medicine, Madison, WI, 2University of Wisconsin, Madison, School of Medicine and Public Health, Madison, WI, 3University of Wisconsin, Madison, Department of Nephrology, Madison, WI, 4University of Wisconsin School of Medicine and Public Health, Madison, WI, 5University of Madison, School of Medicine and Public Health, Madison, WI

    Background/Purpose: Clinical response to Mycophenolic acid (MPA) is highly heterogeneous; thus, therapeutic drug monitoring (TDM) of MPA could help improve treatment efficacy. Our objective in…
  • Abstract Number: 2645 • ACR Convergence 2025

    Age-specific Incidence of Systemic Lupus Erythematosus in the United States: A Meta-Analysis of Data from the Centers for Disease Control and Prevention Lupus Registries

    Peter Izmirly1, Elizabeth Ferucci2, Aimee Hersh3, Mary Beth Son4, Cristina Drenkard5, S. Sam Lim6, Cynthia Crowson7, Ali Duarte-Garcia8, Jill Buyon9, Heather Gold9, Maria Dall'Era10, Patti Katz11, Laura Plantinga12, Jinoos Yazdany13, Jennifer Reihm14, Emily Somers15 and Hilary Parton16, 1New York University Grossman School of Medicine, New York, NY, 2Alaska Native Tribal Health Consortium, Anchorage, AK, 3University of Utah, Salt Lake City, UT, 4Boston Children's Hospital, Boston, MA, 5Rollins School of Public Health, Emory University, Atlanta, Georgia, USA, Acworth, GA, 6Emory University School of Medicine, Atlanta, GA, 7Mayo Clinic, Stewartvillle, MN, 8Mayo Clinic, Rochester, MN, 9NYU Grossman School of Medicine, New York, NY, 10Division of Rheumatology, University of California, San Francisco, CA, 11UCSF, San Rafael, CA, 12University of California, San Francisco, San Francisco, CA, 13UCSF, San Francisco, CA, 14University of California, San Francisco, San Francisco, 15University of Michigan, Ann Arbor, MI, 16New York City Department of Health and Mental Hygiene, New York

    Background/Purpose: Current estimates for age of SLE onset are limited, particularly for males and racial/ethnic groups in the United States. Leveraging five Centers for Disease…
  • Abstract Number: 0845 • ACR Convergence 2025

    Machine Learning–Based Skin Transcriptome Classifier (v2.0) Links SSc Molecular Subtypes to Disease Severity and Progression

    Zhiyun Gong1, Rezvan Parvizi2, Helen Jarnagin1, Haobin Chen3, Madeline Morrisson4, Tammara Wood5, Monique Hinchcliff6, Dinesh Khanna7 and Michael Whitfield8, 1Dartmouth College, Lebanon, NH, 2Dartmouth, lebanon, NH, 3Dartmouth Collge, Lebanon, NH, 4Geisel School of Medicine at Dartmouth College, Hanover, NH, 5Dartmouth, Hanover, NH, 6Yale School of Medicine, Westport, CT, 7University of Michigan, Ann Arbor, MI, 8Geisel School of Medicine, Lebanon, NH

    Background/Purpose: Systemic Sclerosis (SSc) is a clinically and molecularly heterogeneous autoimmune disease. We identified five intrinsic molecular subtypes in SSc by applying semi-supervised machine learning…
  • Abstract Number: 2643 • ACR Convergence 2025

    Microbiome Signatures in RA Treatment: Personalizing Methotrexate Therapy

    Rahul Bodkhe1, Kai Trepka1, Diego Orellana1, Rebecca Blank2, Peter Turnbaugh3, Jose Scher4 and Renuka Nayak5, 1University of California San Francisco, San Francisco, CA, 2NYU Langone Health, New York, NY, 3University of California, San Francisco, San Francisco, CA, 4New York University School of Medicine, New York, NY, 5University of California, San Francisco (UCSF), San Francisco, CA

    Background/Purpose: Rheumatoid arthritis (RA) is a common systemic autoimmune disease that targets the joints, causing persistent pain and swelling. Oral methotrexate (MTX) remains first-line therapy…
  • Abstract Number: 0805 • ACR Convergence 2025

    Safety and Efficacy of Hydroxychloroquine According to Weight-based Dose: Results of a Global Systematic Review and Meta-analysis

    Jacquelyn Nestor1, Zahraa Qamhieh2, Shivani Garg3 and April Jorge1, 1Massachusetts General Hospital, Boston, MA, 2University of Wisconsin, Madison, Department of Medicine, Madison, WI, 3University of Madison, School of Medicine and Public Health, Madison, WI

    Background/Purpose: Hydroxychloroquine (HCQ) is a foundational therapy in systemic lupus erythematosus (SLE) treatment, as it prolongs disease-free and damage-free survival. However, the optimal dose is…
  • Abstract Number: 2316 • ACR Convergence 2025

    Sexual Dysfunction in Women with Axial Spondyloarthritis: A Meta-Analysis of FSFI Total and Domain Scores

    Gabriela Moreira1, Hemerli De Cinque Almeida Esteves2, Nicole Felix3 and Jose Fernando Verztman1, 1Hospital Federal dos Servidores do Estado do Rio de Janeiro, Rio de Janeiro, Rio de Janeiro, Brazil, 2No current affiliation, Columbus, OH, 3Federal University of Campina Grande, Fortaleza, Ceara, Brazil

    Background/Purpose: Beyond musculoskeletal manifestations, there is growing recognition of the systemic and psychosocial burden of axial spondyloarthritis (axSpA). Sexual health is an often-overlooked aspect of…
  • Abstract Number: 0731 • ACR Convergence 2025

    The Efficacy of Leflunomide in the Treatment of Giant Cell Arteritis: A Systematic Review and Meta-Analysis

    Linda Zhu1, Arielle Mendel2, Carolyn Ross3 and Jean-Paul Makhzoum1, 1Universite de Montreal, Montreal, Canada, 2McGill University Health Centre, Montréal, QC, Canada, 3University of Montreal, Longueuil, Canada

    Background/Purpose: The objective of this systematic review is to assess the effectiveness of leflunomide in the treatment of new-onset, refractory or relapsing giant cell arteritis…
  • Abstract Number: 2259 • ACR Convergence 2025

    Lung Transplant Outcomes in Patients with Rheumatoid Arthritis Associated Interstitial Lung Disease Compared to Idiopathic Pulmonary Fibrosis: A Multicentric Retrospective Analysis and Meta-analysis

    Saud AlHajeri1, Matthew Major2, Darya S. Jalaledin3, Beatrice Daviault4, Arusa Shah5, Alec Yu6, Sabrina Hoa7, Robert Levy8, Jennifer Wilson1, Charles Poirier4, James Choi6, John Yee6, Océane Landon-Cardinal9, Kun Huang10 and Hyein Kim11, 1UBC, Vancouver, BC, Canada, 2University of British Columbia, Vancouver, Canada, 3Université de Montréal, Saint-Lambert, QC, Canada, 4University of Montreal, Montreal, QC, Canada, 5University of Montreal, Montreal, BC, Canada, 6University of British Columbia, Vancouver, BC, Canada, 7University of Montreal, Brossard, QC, Canada, 8University of British Columbia, Deerfield, IL, 9Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, 10University of British Columbia, Vancouver, Surrey, BC, Canada, 11The University of British Columbia, Vancouver, BC, Canada

    Background/Purpose: Interstitial lung disease (ILD) is a frequent complication of rheumatoid arthritis (RA), ranging from subclinical ILD to advanced fibrosis, and is associated with significant…
  • Abstract Number: 0545 • ACR Convergence 2025

    Temporal trends in the phenotype and treatment outcomes in axial spondyloarthritis patients included in randomized clinical trials over 25 years: a systematic literature review and meta-regression analysis

    Omar-Javier Calixto1, Uta Kiltz2, Brikena Lalazi3, Franziska Neinert3, Philipp Sewerin4 and Xenofon Baraliakos2, 1Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Cellular and Molecular Immunology Group (InmuBo), Universidad El Bosque, Herne, Nordrhein-Westfalen, Germany, 2Rheumazentrum Ruhrgebiet Herne, Ruhr-University Bochum, Herne, Germany, 3Rheumazentrum Ruhrgebiet, Herne, Germany, 4Rheumazentrum Ruhrgebiet Herne; Ruhr-Universität Bochum, Germany, Herne, Germany

    Background/Purpose: The phenotypes of axial spondyloarthritis (axSpA) and clinical responses to placebo and study drugs in randomized controlled trials (RCTs) have changed over time. We…
  • Abstract Number: 2255 • ACR Convergence 2025

    Diagnostic Accuracy of Anti-Carbamylated Protein Antibodies in Rheumatoid Arthritis: A Systematic Review and Meta-analysis

    Pannathorn Nakaphan1, Patavee Pajareya2, Priabprat Jansem3, Somkiat Phutinart2, Nattanicha Chaisrimaneepan4 and Noppachai Siranart2, 1Department of Internal Medicine, Weiss Memorial Hospital, Chicago, IL, 2Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand, 3Department of Psychiatry, Faculty of Medicine, Prince of Songkla University, Songkhla, Thailand, 4Department of Medicine, Texas Tech University Health Sciences Center, Lubbock, TX

    Background/Purpose: Anti-carbamylated protein antibodies (anti-CarP Ab) are emerging serologic markers in rheumatoid arthritis (RA). Anti-CarP Ab has a controversial diagnostic utility in RA but may…
  • Abstract Number: 0490 • ACR Convergence 2025

    Infection Risks Associated with Monotherapy and Combination Therapies Using Biological or Targeted – DMARD in RA: A Systematic Review and Network Meta-analysis

    Li Liu1, Xue-Mei Zhang1, Zhi-Chun Gu1 and Jia Li2, 1Ren Ji Hospital, Shanghai Jiao Tong University School Of Medicine, Pu Dong Xin Qu, Shanghai, China (People's Republic), 2Department of Rheumatology, Renji Hospital, Shanghai Jiao Tong University School of Medicine, Shanghai, China (People's Republic)

    Background/Purpose: This study aimed to evaluate the infection risks in patients with rheumatoid arthritis (RA) treated with biological or targeted synthetic disease-modifying antirheumatic drugs (b/tsDMARDs),…
  • Abstract Number: 1732 • ACR Convergence 2025

    Incidence of Flares in Pre-existing Rheumatologic Diseases Among Patients with Solid Tumors Undergoing Cancer Immunotherapy: A Systematic Review and Meta-analysis

    Takemichi Matsui1, Kenji Yamada2, Toshiaki Takahashi3, Yoshito Nishimura4 and Yu Fujiwara5, 1Department of Medicine, Mount Sinai Morningside/West Hospitals, Icahn School of Medicine at Mount Sinai, New York, NY, 2Department of Allergy and Rheumatology, Kameda Medical Center, Chiba, Japan, 3Department of Medicine, John A. Burns School of Medicine, University of Hawaii, Honolulu, HI, 4Division of Hematology/Oncology, Mayo Clinic, Rochester, MN, 5Department of Medicine, Roswell Park Comprehensive Cancer Center, Buffalo, NY

    Background/Purpose: Immune checkpoint inhibitors (ICIs) have become essential in cancer treatment, offering significant survival benefits across various malignancies. However, ICIs can cause immune-related Adverse Events…
  • Abstract Number: 0334 • ACR Convergence 2025

    Diagnostic Test Accuracy of Ultrasound for Detecting Knee Osteoarthritis: A Systematic Review and Meta-Analysis

    Mohamed Abdelsalam1, Hadeer Hafez2, Maryam Lasheen3, Bassant Elaraby Elsayed Badwy4, Omar Sameh Nabil El Sedafy1, Menat Alla Ayman Ali Mahdy4, Hazem E. Mohammed5 and Mohamed Reda Awad6, 1Misr University For Science and Technology, 6 october, Al Jizah, Egypt, 26th October University, 6 october, Al Jizah, Egypt, 3Misr University For Science and Technology, Helwan, Al Qahirah, Egypt, 4Misr University For Science and Technology, Nasr City, Al Qahirah, Egypt, 5Faculty of Medicine, Assiut university, Assiut, Egypt, assyut, Asyut, Egypt, 6Al Azhar University, Cairo, Egypt, Giza, Al Jizah, Egypt

    Background/Purpose: Ultrasound (US) is an emerging, promising imaging modality offering a safe, radiation-free, and cost-effective option for diagnosing and assessing structural changes in knee osteoarthritis…
  • Abstract Number: 1685 • ACR Convergence 2025

    The Sjögren’s Tool for Assessing Response (STAR) demonstrates its ability to accurately detect treatment efficacy in 11 recent RCTs in Sjögren’s disease

    Raphaele Seror1, Gabriel Baron2, Elodie Perrodeau3, Alena Piatrova4, Hendrika Bootsma5, Simon Bowman6, Jacques-eric GOTTENBERG7, Divi Cornec8, michele Bombardieri9, Suzanne Arends10, Benjamin A. Fisher11, Wolfgang Hueber12, Antoine Sreih13, Antonia Christodoulou14, Andre van Maurik15, Joel van Roon16, Valerie Devauchelle17, Peter Gergely18, Xavier Mariette19 and Raphael Porcher20, 1Department of Rheumatology, National referral center for auto immune disease and Sjogren disease, Université Paris-Saclay, INSERM UMR1184: Centre for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, Paris, France., le kremlin bicetre, France, 2Hôtel-Dieu, Université Paris Cité,, Paris, France, 3Université Paris Descartes Sorbonne Paris Cité, Paris, France, 4Department of Rheumatology, National referral center for auto immune disease and Sjogren disease, Université Paris-Saclay, INSERM UMR1184: Centre for Immunology of Viral Infections and Autoimmune Diseases, Assistance Publique-Hôpitaux de Paris, Hôpital Bicêtre, Le Kremlin Bicêtre, Paris, France., Paris, Ile-de-France, France, 5UMCG, Groningen, Netherlands, 6University Hospitals Birmingham, Birmingham, United Kingdom, 7Hautepierre Hospital, STRASBOURG, Alsace, France, 8Departement of Rhumatology, CHU Brest, Université de Brest, INSERM UMR1227: LBAI, Brest, France, Brest, France, 9Experimental Medicine and Rheumatology, William Harvey Research Institute, Queen Mary University of London, UK, London, United Kingdom, 10University Medical Center Groningen, Groningen, Netherlands, 11King’s College London, London, UK; Institute of Inflammation and Ageing, University of Birmingham, Birmingham, UK, Birmingham, United Kingdom, 12Novartis Pharmaceuticals, Basel, Switzerland, 13Cullinan Therapeutics, New York, NY, 14BMS, Princeton, NJ, 15GlaxoSmithKline, Stevenage, United Kingdom, 16Center of Translational Immunology, Department of Immunology and Department of Rheumatology & Clinical Immunology, University Medical Center Utrecht, Utrecht University, Utrecht PO BOX 85500, 3508 GA, Netherlands, Utrecht, Netherlands, 17UBO, Brest, France, 18Novartis Biomedical Research, Basel, Switzerland, 19Université Paris-Saclay, Le Kremlin Bicetre, France, 20Université Paris Cité and Université Sorbonne Paris Nord, INSERM, INRAE, Center for Research in Epidemiology and StatisticS (CRESS), Paris, France, Paris, France

    Background/Purpose: Performance of the recently developed composite responder index STAR is highly awaited. We conduscted this study to evaluate the performance of STAR in previously…
  • Abstract Number: 0333 • ACR Convergence 2025

    Diagnostic Test Accuracy of Artificial Intelligence in Early Diagnosis of Osteoarthritis: A Systematic Review and Meta-Analysis of 45,588 Knees

    Mohamed Abdelsalam1, Hadeer Hafez2, Omar Sameh Nabil El Sedafy1, Nourhan Abouelella3, Ahmed Abdulhafeez Hamza3, Omnia Samy El-Sayed4, Mohamed Reda Awad5, Gihan Omar3 and Hazem E. Mohammed6, 1Misr University For Science and Technology, 6 october, Al Jizah, Egypt, 26th October University, 6 october, Al Jizah, Egypt, 3Faculty of Medicine, Misr University for Science and Technology, 6 october, Al Jizah, Egypt, 4Misr University For Science and Technology, Nasr City, Al Qahirah, Egypt, 5Al Azhar University, Cairo, Egypt, Giza, Al Jizah, Egypt, 6Faculty of Medicine, Assiut university, Assiut, Egypt, assyut, Asyut, Egypt

    Background/Purpose: Artificial intelligence (AI) rapid advancement opens new opportunities in the field of rheumatology. With better imaging, AI may help find early osteoarthritic changes that…
  • 1
  • 2
  • 3
  • …
  • 13
  • Next Page »
Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

Embargo Policy

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology